Fda approves qfitlia™ (fitusiran), the first sirna (rnai therapeutic) for the treatment of hemophilia a or b

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today highlighted the significance of the u.s. food and drug administration's (fda) approval of qfitlia™ (fitusiran), the sixth alnylam-discovered rnai therapeutic approved in the u.s., and the first and only therapeutic to lower antithrombin (at), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.
ALNY Ratings Summary
ALNY Quant Ranking